Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVDL Hot Sheet
Join SI Premium – FREE
Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68.13 million versus the consensus estimate of $61.4 million.
For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Manulife Financial (MFC) Tops Q3 EPS by 40c
- ONE Group Hospitality (STKS) Misses Q3 EPS by 55c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
